Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

HKG:3737 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	17.29	95.21	162.78	106.39	52.13
Depreciation & Amortization	99.15	108.13	99.48	93.58	82.46
Other Amortization	3.33	3.29	2.6	2.8	2.59
Loss (Gain) From Sale of Assets	1.34	1.2	-0.43	-0.69	-0.11
Loss (Gain) From Sale of Investments	-4.53	3.9	-3.61	-2.43	40.44
Provision & Write-off of Bad Debts	0.76	4.1	0.47	-0.16	0.44
Other Operating Activities	-10.66	-1.16	-15.37	-3.04	-27.84
Change in Accounts Receivable	-16.78	-119.74	-18.22	-13.59	10.03
Change in Inventory	59.13	-22.4	-10.65	-59.79	-21.03
Change in Accounts Payable	-34.36	104.99	1.19	68.95	10.39
Change in Unearned Revenue	2.12	4.88	8.67	10.53	10.57
Change in Other Net Operating Assets	62.91	-0.92	-125.39	82.03	18.31
Operating Cash Flow	179.7	181.48	101.5	284.57	178.38
Operating Cash Flow Growth	-0.98%	78.79%	-64.33%	59.53%	91.44%

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-35.22	-140.76	-169.18	-88.41	-185.85
Sale of Property, Plant & Equipment	1.32	3.82	17.1	21.83	2.53
Sale (Purchase) of Intangibles	-0.05	-1.1	-2.25	-0.74	-2.01
Investment in Securities	-21.22	3.24	-55.45	70.95	22.7
Other Investing Activities	4.03	14.73	7.02	9.76	26.66
Investing Cash Flow	-51.14	-120.06	-202.76	13.38	-135.98

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	-	-	-	123.87
Long-Term Debt Issued	58.9	52.36	49.67	10.5	-
Total Debt Issued	58.9	52.36	49.67	10.5	123.87
Short-Term Debt Repaid	-	-	-	-	-145.54
Long-Term Debt Repaid	-140.67	-83.65	-88.63	-78.67	-45.41
Total Debt Repaid	-140.67	-83.65	-88.63	-78.67	-190.96
Net Debt Issued (Repaid)	-81.77	-31.29	-38.96	-68.16	-67.09
Issuance of Common Stock	-	-	-	-	30.04
Repurchase of Common Stock	-	-3.57	-	-	-4.38
Common Dividends Paid	-38.55	-23.14	-116.15	-	-
Other Financing Activities	-0.38	-0.73	0.49	0.02	0.6
Financing Cash Flow	-120.7	-58.74	-154.62	-68.14	-40.83

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-1.06	0.05	-0.77	-2.18	0.78
Miscellaneous Cash Flow Adjustments	0.52	-	-	-	-
Net Cash Flow	7.32	2.74	-256.64	227.63	2.35

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	144.47	40.72	-67.68	196.17	-7.47
Free Cash Flow Growth	254.76%	-	-	-	-
Free Cash Flow Margin	8.31%	1.84%	-3.30%	10.74%	-0.43%
Free Cash Flow Per Share	0.17	0.05	-0.08	0.23	-0.01
Levered Free Cash Flow	9.17	27.57	-103.76	245.16	-49.32
Unlevered Free Cash Flow	12.53	31.94	-98.84	249.26	-44.89

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	1.95	2.63	2.61	1.92	2.67
Cash Income Tax Paid	12.62	44	42.54	17.37	23.88
Change in Working Capital	73.02	-33.2	-144.41	88.13	28.26

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 31, 2026

Data Sources Report a data error